Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 3
1964 9
1965 84
1966 181
1967 267
1968 329
1969 358
1970 413
1971 423
1972 436
1973 446
1974 438
1975 465
1976 468
1977 469
1978 503
1979 537
1980 582
1981 652
1982 780
1983 821
1984 948
1985 1057
1986 1054
1987 1111
1988 1120
1989 1300
1990 1294
1991 1215
1992 1368
1993 1374
1994 1371
1995 1437
1996 1495
1997 1494
1998 1584
1999 1634
2000 1884
2001 2057
2002 2191
2003 2493
2004 2634
2005 2904
2006 3516
2007 3573
2008 3700
2009 4091
2010 4877
2011 5249
2012 5325
2013 5343
2014 5518
2015 5699
2016 5631
2017 5626
2018 5754
2019 5959
2020 6811
2021 7101
2022 6437
2023 5994
2024 2007

Text availability

Article attribute

Article type

Publication date

Search Results

128,582 results

Results by year

Filters applied: . Clear all
Page 1
Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment.
Falcomatà C, Bärthel S, Widholz SA, Schneeweis C, Montero JJ, Toska A, Mir J, Kaltenbacher T, Heetmeyer J, Swietlik JJ, Cheng JY, Teodorescu B, Reichert O, Schmitt C, Grabichler K, Coluccio A, Boniolo F, Veltkamp C, Zukowska M, Vargas AA, Paik WH, Jesinghaus M, Steiger K, Maresch R, Öllinger R, Ammon T, Baranov O, Robles MS, Rechenberger J, Kuster B, Meissner F, Reichert M, Flossdorf M, Rad R, Schmidt-Supprian M, Schneider G, Saur D. Falcomatà C, et al. Nat Cancer. 2022 Mar;3(3):318-336. doi: 10.1038/s43018-021-00326-1. Epub 2022 Jan 31. Nat Cancer. 2022. PMID: 35122074 Free PMC article.
Targeting leukemia inhibitory factor in pancreatic adenocarcinoma.
Wang J, Karime C, Majeed U, Starr JS, Borad MJ, Babiker HM. Wang J, et al. Expert Opin Investig Drugs. 2023 May;32(5):387-399. doi: 10.1080/13543784.2023.2206558. Epub 2023 Apr 24. Expert Opin Investig Drugs. 2023. PMID: 37092893 Review.
Advances in drug treatments for mesothelioma.
Zucali PA, De Vincenzo F, Perrino M, Digiacomo N, Cordua N, D'Antonio F, Borea F, Fazio R, Pirozzi A, Santoro A. Zucali PA, et al. Expert Opin Pharmacother. 2022 Jun;23(8):929-946. doi: 10.1080/14656566.2022.2072211. Epub 2022 May 9. Expert Opin Pharmacother. 2022. PMID: 35508368
Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma.
Katz MHG, Petroni GR, Bauer T, Reilley MJ, Wolpin BM, Stucky CC, Bekaii-Saab TS, Elias R, Merchant N, Dias Costa A, Lenehan P, Cardot-Ruffino V, Rodig S, Pfaff K, Dougan SK, Nowak JA, Varadhachary GR, Slingluff CL, Rahma O. Katz MHG, et al. J Immunother Cancer. 2023 Dec 1;11(12):e007586. doi: 10.1136/jitc-2023-007586. J Immunother Cancer. 2023. PMID: 38040420 Free PMC article. Clinical Trial.
128,582 results
You have reached the last available page of results. Please see the User Guide for more information.